Premium
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in C hinese T ype 2 diabetic patients
Author(s) -
Dai XingPing,
Huang Qiong,
Yin JiYe,
Guo Yu,
Gong ZhiCheng,
Lei MinXiang,
Jiang TieJian,
Zhou HongHao,
Liu ZhaoQian
Publication year - 2012
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2012.05701.x
Subject(s) - repaglinide , medicine , postprandial , endocrinology , allele , diabetes mellitus , insulin resistance , genotype , insulin , type 2 diabetes , gastroenterology , biology , gene , genetics
Summary The present study evaluated the effects of KCNQ1 rs2237892 and rs2237895 polymorphisms on repaglinide efficacy in C hinese patients with T ype 2 diabetes mellitus ( T 2 DM ). In all, 367 T 2 DM patients and 214 controls were genotyped. Forty of the T 2 DM patients were randomly selected to undergo 8 weeks repaglinide treatment. The frequency of the rs2237892 allele was lower in the T 2 DM patients than in the control group ( P < 0.05). The frequency of the rs2237895 C allele was higher in T 2 DM patients than in healthy control subjects ( P < 0.05). Diabetic patients with the rs2237892 risk C allele had lower fasting insulin levels ( P < 0.01) and homeostasis model assessment of insulin resistance ( HOMA ‐ IR ; P < 0.01) values than carriers of the T allele. Diabetic patients with the rs2237895 risk C allele had higher fasting plasma glucose ( P < 0.01), postprandial plasma glucose ( PPG ) levels ( P < 0.01) and HOMA ‐ IR values ( P < 0.01) than those with the A allele. Following repaglinide treatment, those T 2 DM patients with the rs2237892 T allele and rs2237895 C allele were more likely to have a positive response to repaglinide in terms of PPG levels ( P < 0.05) than T 2 DM patients with the rs2237892 CC and rs2237895 AA genotypes. In conclusion, KCNQ1 rs2237892 and rs2237895 polymorphisms were found to be associated with the therapeutic efficacy of repaglinide in C hinese T 2 DM patients.